Hyperglycemia has been reported in 16% of patients using capivasertib, though severe, life-threatening cases such as DKA or hyperosmolar hyperglycemic state occur in only 0.3% of patients [4]. AKT inhibition is believed to be the primary cause of hyperglycemia associated with capivasertib, as AKT plays a key role in insulin signaling by facilitating tissue glucose uptake and promoting hepatic glycogen storage [4]. Here, AKT1 is linked to Hyperglycemia.